Didier Combis Director B.U. Exclusive Synthesis & PharmaChemicals – PCAS
Click HERE to download the PDF version
WHAT PARTS OF THE MARKET ARE DRIVING GROWTH FOR PCAS?
Besides our Specialty Chemical business which is doing well and focusing on highly complex chemicals mainly for the electronic industry, the pharma segment is extremely important and is a major growth driver for PCAS. In the past two years most of our growth came from custom manufacturing of pharma chemicals, APIs and GMP intermediates.
In December 2016 we acquired from Covance a major development center, West of Paris that was originally built by Sanofi. This is a fantastic opportunity for us, since we wanted to find a large and first class facility to concentrate all our API development capabilities in one place and this former Sanofi-Covance facility is next door to one of our API sites located 45 km from Paris. It can host up to 200 scientists and will boost ...